Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes

A Consensus Report

Diane K. Wherrett, Jane L. Chiang, Alan M. Delamater, Linda DiMeglio, Stephen E. Gitelman, Peter A. Gottlieb, Kevan C. Herold, Daniel J. Lovell, Trevor J. Orchard, Christopher M. Ryan, Desmond A. Schatz, David S. Wendler, Carla J. Greenbaum

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

Original languageEnglish (US)
Pages (from-to)1975-1985
Number of pages11
JournalDiabetes Care
Volume38
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Therapeutics
Industry
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Wherrett, D. K., Chiang, J. L., Delamater, A. M., DiMeglio, L., Gitelman, S. E., Gottlieb, P. A., ... Greenbaum, C. J. (2015). Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. Diabetes Care, 38(10), 1975-1985. https://doi.org/10.2337/dc15-1429

Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes : A Consensus Report. / Wherrett, Diane K.; Chiang, Jane L.; Delamater, Alan M.; DiMeglio, Linda; Gitelman, Stephen E.; Gottlieb, Peter A.; Herold, Kevan C.; Lovell, Daniel J.; Orchard, Trevor J.; Ryan, Christopher M.; Schatz, Desmond A.; Wendler, David S.; Greenbaum, Carla J.

In: Diabetes Care, Vol. 38, No. 10, 01.10.2015, p. 1975-1985.

Research output: Contribution to journalArticle

Wherrett, DK, Chiang, JL, Delamater, AM, DiMeglio, L, Gitelman, SE, Gottlieb, PA, Herold, KC, Lovell, DJ, Orchard, TJ, Ryan, CM, Schatz, DA, Wendler, DS & Greenbaum, CJ 2015, 'Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report', Diabetes Care, vol. 38, no. 10, pp. 1975-1985. https://doi.org/10.2337/dc15-1429
Wherrett, Diane K. ; Chiang, Jane L. ; Delamater, Alan M. ; DiMeglio, Linda ; Gitelman, Stephen E. ; Gottlieb, Peter A. ; Herold, Kevan C. ; Lovell, Daniel J. ; Orchard, Trevor J. ; Ryan, Christopher M. ; Schatz, Desmond A. ; Wendler, David S. ; Greenbaum, Carla J. / Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes : A Consensus Report. In: Diabetes Care. 2015 ; Vol. 38, No. 10. pp. 1975-1985.
@article{bad4c73a7b0f4bb6870d65544202a8fb,
title = "Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report",
abstract = "Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.",
author = "Wherrett, {Diane K.} and Chiang, {Jane L.} and Delamater, {Alan M.} and Linda DiMeglio and Gitelman, {Stephen E.} and Gottlieb, {Peter A.} and Herold, {Kevan C.} and Lovell, {Daniel J.} and Orchard, {Trevor J.} and Ryan, {Christopher M.} and Schatz, {Desmond A.} and Wendler, {David S.} and Greenbaum, {Carla J.}",
year = "2015",
month = "10",
day = "1",
doi = "10.2337/dc15-1429",
language = "English (US)",
volume = "38",
pages = "1975--1985",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes

T2 - A Consensus Report

AU - Wherrett, Diane K.

AU - Chiang, Jane L.

AU - Delamater, Alan M.

AU - DiMeglio, Linda

AU - Gitelman, Stephen E.

AU - Gottlieb, Peter A.

AU - Herold, Kevan C.

AU - Lovell, Daniel J.

AU - Orchard, Trevor J.

AU - Ryan, Christopher M.

AU - Schatz, Desmond A.

AU - Wendler, David S.

AU - Greenbaum, Carla J.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

AB - Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

UR - http://www.scopus.com/inward/record.url?scp=84962406567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962406567&partnerID=8YFLogxK

U2 - 10.2337/dc15-1429

DO - 10.2337/dc15-1429

M3 - Article

VL - 38

SP - 1975

EP - 1985

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -